Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a topical combination drug consisting of didecyldimethylammonium chloride (a quaternary ammonium compound with broad-spectrum antimicrobial activity) and prednicarbate (a medium-potency topical corticosteroid). Didecyldimethylammonium chloride acts as a bactericidal and fungicidal agent, disrupting microbial cell membranes. Prednicarbate reduces inflammation by inhibiting cytokine production in skin cells. The combination has been studied for the treatment of impetiginized eczema—eczema complicated by secondary bacterial infection—where it aims to address both infection and inflammation[1][4][5]. Didecyldimethylammonium chloride is also known for its use as a disinfectant in non-pharmaceutical settings, but in this context serves as an adjunctive antimicrobial agent. Prednicarbate is valued for its anti-inflammatory effects with lower risk of skin atrophy compared to other corticosteroids[9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on didecyldimethylammoniumchloride + prednicarbate.